LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) granted an inducement equity award to new General Counsel Dr. Minako Pazdera on February 10, 2026 under the Nasdaq Listing Rule 5635(c)(4) exception.

Dr. Pazdera received options to buy 140,000 shares, with a 10-year term, $24.22 exercise price (closing price on grant date) and four-year vesting (25% after one year, then monthly).

Key Figures

Option grant size: 140,000 options Option term: 10 years Exercise price: $24.22 per share +5 more

8 metrics

Option grant size 140,000 options Inducement award to new General Counsel on Feb 10, 2026

Option term 10 years Ten-year term for inducement stock options

Exercise price $24.22 per share Equal to closing price on Feb 10, 2026 grant date

Vesting period 4 years Options vest over four years subject to continuous service

Initial vesting 25% after 1 year Quarter of option shares vest on first anniversary of grant

Ongoing vesting rate 1/48th monthly Remaining options vest monthly after first year

Current share price $24.22 Price before article publication, used as option exercise price

52-week range $13.36–$24.9499 Price range prior to inducement grant announcement

Market Reality Check

Price: $24.22 Vol: Volume 143,418 vs 20-day ...

normal vol

$24.22 Last Close

Volume Volume 143,418 vs 20-day average 206,282 (relative volume 0.7x) ahead of this inducement grant filing. normal

Technical Shares at $24.22, trading above 200-day MA of $18.27 and within -2.93% of the 52-week high.

Peers on Argus

Peers show mixed, mostly modest moves, with ABEO +0.2%, ASMB +2.12%, RCKT +1.57%...

Peers show mixed, mostly modest moves, with ABEO +0.2%, ASMB +2.12%, RCKT +1.57%, while DRUG -1.76% and LRMR -2.06%, suggesting today’s context is more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Private placement financing	Positive	+12.7%	Raised about $100M via private placement to fund LB-102 Phase 2 trial.
Jan 26	Clinical trial start	Positive	-6.4%	Initiated Phase 2 ILLUMINATE-1 bipolar depression trial for LB-102.
Jan 21	Executive appointment	Positive	+0.7%	Appointed experienced General Counsel to support LB-102 and CNS strategy.
Jan 12	Inducement option grants	Neutral	+4.0%	Granted stock options to two senior hires under inducement grant rule.
Jan 06	Leadership expansion	Positive	-3.3%	Added senior leaders in Corporate Affairs and People & Culture as LB-102 advances.

Pattern Detected

News flow over the past month shows mixed price reactions: financing and select leadership or option-related updates have seen positive moves, while some clinical and leadership headlines drew negative responses.

Recent Company History

Over the last month, LB Pharmaceuticals has combined financing, clinical progress, and leadership build-out. A $100.0 million private placement on Feb 5, 2026 to fund LB-102 development was followed by a strong +12.71% move. The Phase 2 ILLUMINATE-1 bipolar depression trial launch on Jan 26, 2026 saw a -6.4% reaction despite its strategic importance. Leadership appointments and prior inducement grants in early January produced modestly mixed moves, indicating investors react variably to non-clinical corporate updates.

Market Pulse Summary

This announcement details a standard inducement equity grant of 140,000 options at $24.22 under Nasd...

Analysis

This announcement details a standard inducement equity grant of 140,000 options at $24.22 under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years. It follows recent leadership appointments and financing that support LB-102’s development. Investors monitoring governance and dilution frameworks may focus on how such grants fit within the 2025 Equity Incentive Plan and overall hiring strategy, while key milestones remain tied to LB-102 clinical timelines and execution on recently funded trials.

Key Terms

inducement grant, nasdaq listing rule 5635(c)(4), equity award, equity incentive plan, +2 more

6 terms

inducement grant regulatory

"pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4)"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

equity award financial

"it has granted to Dr. Minako Pazdera ... an equity award outside of, but subject to the terms"

An equity award is a form of pay where a company gives employees, executives or other stakeholders the right to own or buy company shares—either immediately or after meeting certain conditions. Think of it like receiving slices of the company pie now or coupons to claim slices later; it matters to investors because it affects ownership dilution, executive incentives and reported compensation costs, and signals how management is being rewarded and retained.

equity incentive plan financial

"subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

exercise price financial

"an exercise price per share equal to $24.22, which was the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB Pharmaceuticals, an equity award outside of, but subject to the terms and conditions of, the LB Pharmaceuticals Inc 2025 Equity Incentive Plan. The equity award was granted on February 10, 2026, pursuant to the “inducement grant” exception provided under Nasdaq Listing Rule 5635(c)(4) as an inducement material to Dr. Pazdera entering into employment with LB Pharmaceuticals.

Dr. Pazdera received options to purchase 140,000 shares of LB Pharmaceuticals’ common stock. The options carry a ten-year term and an exercise price per share equal to $24.22, which was the closing price of LB Pharmaceuticals’ common stock on the date of grant, and vests over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48^th of the shares vesting monthly thereafter, subject to continuous service through the applicable vesting dates.

About LB-102

LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotics outside the U.S., LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. A Phase 2 clinical trial of LB-102 for bipolar depression is ongoing, and the Company expects to initiate a Phase 3 trial of LB-102 for schizophrenia in 1Q 2026, and a Phase 2 clinical trial for the adjunctive treatment of major depressive disorder in early 2027. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases.

About LB Pharmaceuticals

LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Media and Investor Contact
Ellen Rose
erose@lbpharma.us

FAQ

What equity inducement did LB Pharmaceuticals (LBRX) grant to its new General Counsel on February 10, 2026?

LB Pharmaceuticals granted Dr. Minako Pazdera options to purchase 140,000 shares as an inducement award. According to the company, the grant was made under Nasdaq Listing Rule 5635(c)(4) to recruit Dr. Pazdera into employment.

What are the exercise price and term of the LBRX inducement stock options granted February 10, 2026?

The options carry a 10-year term with an exercise price of $24.22 per share. According to the company, $24.22 was the closing price of LBRX common stock on the grant date.

How do the LBRX inducement options to Dr. Minako Pazdera vest over time?

The options vest over four years: 25% after one year, then 1/48th monthly thereafter. According to the company, vesting is subject to continuous service through each applicable vesting date.

Why did LB Pharmaceuticals (LBRX) use Nasdaq Listing Rule 5635(c)(4) for this equity grant?

LB Pharmaceuticals used the Nasdaq inducement exception to grant equity material to hiring Dr. Pazdera. According to the company, the award was provided as an inducement to enter into employment under Rule 5635(c)(4).